Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Steglatro (ertugliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• This summary is based on the review of 17 systematic review(s)/meta-analysis(es). ^[1-17]
• Ertugliflozin reduced HbA1c levels by -0.77% for 5 mg and -0.82% for 15 mg doses compared to placebo. A meta-analysis reported a WMD of -0.641% versus placebo and -0.215% versus other hypoglycemic agents. Ertugliflozin 15 mg showed greater HbA1c reduction than dapagliflozin 10 mg and empagliflozin 25 mg in indirect comparisons.
• Ertugliflozin reduced FPG by -1.62 mmol/L for the 5 mg dose. A WMD of -1.249 mmol/L versus placebo and -0.266 mmol/L versus other hypoglycemic agents was reported in another study.
• Ertugliflozin led to significant weight loss of -1.87 kg for the 5 mg dose and -1.774 kg in a meta-analysis.
• Ertugliflozin significantly reduced SBP by -3.64 mmHg and DBP by -1.13 mmHg. SBP reductions of -3.3 to -3.5 mmHg were noted in East/Southeast Asian patients.
• Ertugliflozin was associated with a significant increase in the risk of genital mycotic infections (RR 4.34 for 5 mg dose) but did not significantly increase the risk of urinary tract infections, hypoglycemia, acute kidney injury, diabetic ketoacidosis, or fractures.
• There were no significant differences in the incidence of serious adverse events for ertugliflozin compared to other treatments.
• Both female and male subgroups exhibited an elevated risk of genital mycotic infections with ertugliflozin.
• Ertugliflozin demonstrated significant reductions in HbA1c, FPG, body weight, and SBP in East/Southeast Asian patients, as evaluated in a dedicated post-hoc analysis.
• Studies included patients with T2DM, heart failure, and chronic kidney disease. Ertugliflozin was less effective in preventing composite cardiovascular outcomes in patients with heart failure compared to other SGLT2 inhibitors.